The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments

Neurosurgical Focus

Volumn 30, Issue 5, 2011, Pages

  Choy, Winward C ^a   Kim, Won ^a   Nagasawa, Daniel ^a   Stramotas, Stephanie ^a   Yew, Dndrew ^a   Gopen, Quinton ^a   Parsa, Andrew T ^b   Yang, Isaa C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Meningioma; Molecular genetics; Pathogenesis; Signaling pathway

Indexed keywords

CHROMOSOME 22; CHROMOSOME ABERRATION; DISEASE COURSE; GENETICS; HUMAN; MENINGIOMA; MONOSOMY; REVIEW; SIGNAL TRANSDUCTION;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 22; DISEASE PROGRESSION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MONOSOMY; SIGNAL TRANSDUCTION;

EID: 79955739835     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2011.2.FOCUS1116     Document Type: Review

References (134)

1. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M: Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210-218, 2004.
2. Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, Lal A: Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia 10:604-612, 2008.
3. Bale AE: Hedgehog signaling and human disease. Annu Rev Genomics Hum Genet 3:47-65, 2002.
4. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al: p14ARF links the tumour suppressors RB and p53. Nature 395:124-125, 1998.
5. Bickerstaff ER, Small JM, Guest IA: The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21:89-91, 1958.
6. Bitzer M, Wöckel L, Luft AR, Wakhloo AK, Petersen D, Opitz H, et al: The importance of pial blood supply to the development of peritumoral brain edema in meningiomas. J Neurosurg 87:368-373, 1997.
7. Black PM: Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 24: 302-306, 1997.
8. Bolós V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocr Rev 28:339-363, 2007.
9. Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al: Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159:661-669, 2001.
10. Briscoe J, Thérond P: Hedgehog signaling: from the Drosophila cuticle to anti-cancer drugs. Dev Cell 8:143-151, 2005.
11. Büschges R, Boström J, Wolter M, Blaschke B, Weber RG, Lich ter P, et al: Analysis of human meningiomas for aberrations of the MADH2, MADH4, APM-1 and DCC tumor suppressor genes on the long arm of chromosome 18. Int J Cancer 92:551-554, 2001.
12. Büschges R, Ichimura K, Weber RG, Reifenberger G, Collins VP: Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 12: 145-153, 2002.
13. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Klein-schmidt-Demasters BK, Perry A: Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 60:628-636, 2001.
14. Capobianco AJ, Zagouras P, Blaumueller CM, Artavanis-Tsakonas S, Bishop JM: Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2. Mol Cell Biol 17:6265-6273, 1997.
15. Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, et al: Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87:315-323, 1997.
16. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology 62: 1210-1212, 2004.
17. Cook KM, Figg WD: Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222-243, 2010.
18. Duda DG, Jain RK, Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemo-radiation for solid cancers. J Clin Oncol 25:4033-4042, 2007.
19. Falchetti ML, Larocca LM, Pallini R: Telomerase in brain tumors. Childs Nerv Syst 18:112-117, 2002.
20. Gerber MA, Bahr SM, Gutmann DH: Protein 4 1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res 66: 5295-5303, 2006.
21. Grönholm M, Sainio M, Zhao F, Heiska L, Vaheri A, Carpén O: Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci 112:895-904, 1999.
22. Guertin DA, Sabatini DM: Defning the role of mTOR in cancer. Cancer Cell 12:9-22, 2007.
23. Gupta V, Samuleson CG, Su S, Chen TC: Nelfnavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus 23(4):E9, 2007.
24. Gutmann DH, Hirbe AC, Haipek CA: Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet 10:1519-1529, 2001.
25. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA: The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 8:266-278, 2001.
26. Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, Hendrix M: Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 8:267-275, 1999.
27. Halper J, Jung C, Perry A, Suliman H, Hill MP, Scheithauer B: Expression of TGFalpha in meningiomas. J Neurooncol 45: 127-134, 1999.
28. Hanft S, Canoll P, Bruce JN: A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol 99:433-443, 2010.
29. Harada T, Irving RM, Xuereb JH, Barton DE, Hardy DG, Moffat DA, et al: Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 84:847-851, 1996.
30. Harrison MJ, Wolfe DE, Lau TS, Mitnick RJ, Sachdev VP: Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg 75: 564-574, 1991.
31. Hidalgo M, Maitra A: The hedgehog pathway and pancreatic cancer. N Engl J Med 361:2094-2096, 2009.
32. Hsu DW, Efrd JT, Hedley-Whyte ET: Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113-120, 1997.
33. Huang S, Lichtenauer UD, Pack S, Wang C, Kim AC, Lutch-man M, et al: Reassignment of the EPB4.1 gene to 1p36 and assessment of its involvement in neuroblastomas. Eur J Clin Invest 31:907-914, 2001.
34. Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca EA: Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg 91: 85-92, 1999.
35. Iso T, Kedes L, Hamamori Y: HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194:237-255, 2003.
36. Jääskeläinen J, Haltia M, Laasonen E, Wahlström T, Valtonen S: The growth rate of intracranial meningiomas and its relation to histology. An analysis of 43 patients. Surg Neurol 24: 165-172, 1985.
37. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al: NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29:4250-4261, 2009.
38. James MF, Manchanda N, Gonzalez-Agosti C, Hartwig JH, Ramesh V: The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the flaments through a lateral association. Biochem J 356:377-386, 2001.
39. Jannatipour M, Dion P, Khan S, Jindal H, Fan X, Laganière J, et al: Schwannomin isoform-1 interacts with syntenin via PDZ domains. J Biol Chem 276:33093-33100, 2001.
40. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ: Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848-853, 2003.
41. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, et al: Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 94:218-221, 2001.
42. Johnson MD, Woodard A, Kim P, Frexes-Steed M: Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 94:293-300, 2001.
43. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS: Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neurooncol 56:133-142, 2002.
44. Katoh Y, Katoh M: Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 4:1050-1054, 2005.
45. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008.
46. Kim YS, Lewandoski M, Perantoni AO, Kurebayashi S, Na-kanishi G, Jetten AM: Identification of Glis1, a novel Gli-related, Kruppel-like zinc finger protein containing transactiva-tion and repressor functions. J Biol Chem 277:30901-30913, 2002.
47. Kino T, Takeshima H, Nakao M, Nishi T, Yamamoto K, Kimura T, et al: Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6:441-454, 2001.
48. Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, et al: Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43: 280-290, 2003.
49. Kopan R: Notch: a membrane-bound transcription factor. J Cell Sci 115:1095-1097, 2002.
50. Koziel L, Wuelling M, Schneider S, Vortkamp A: Gli3 acts as a repressor downstream of Ihh in regulating two distinct steps of chondrocyte differentiation. Development 132:5249-5260, 2005.
51. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI: NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090-1100, 2003.
52. Lamszus K: Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275-286, 2004.
53. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, West-phal M: Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110:103-110, 1999.
54. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergün S, Westphal M: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 46:938-948, 2000.
55. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Wright WE, Shay JW: Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28:416-420, 1997.
56. Laurendeau I, Ferrer M, Garrido D, DHaene N, Ciavarelli P Basso A, et al: Gene expression prof ' ling of the hedgehog signaling pathway in human meningiomas. Mol Med 16:262-270, 2010.
57. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestaña A, et al: NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 18:2231-2239, 1999.
58. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139, 1998.
59. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK: Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416-425, 2005.
60. Lomas J, Bello MJ, Arjona D, Gonzalez-Gomez P, Alonso ME, de Campos JM, et al: Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet Cytogenet 129:88-91, 2001.
61. Longstreth WT Jr, Phillips LE, Drangsholt M, Koepsell TD, Custer BS, Gehrels JA, et al: Dental x-rays and the risk of intracranial meningioma: a population-based case-control study. Cancer 100:1026-1034, 2004.
62. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Callaghan R, Collado M, Roldan P, et al: Association of loss of 1p and alterations of chromosome 14 in meningioma progression. Cancer Genet Cytogenet 148:123-128, 2004.
63. López-Ginés C, Gil-Benso R, Collado-Díaz M, Gregori-Romero M, Roldán P, Barberá J, et al: [Meningioma: a model of cytogenetic evolution in tumoral initiation and progresion.] Neurocirugia (Astur) 14:517-525, 2003 (Span).
64. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF: Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluogrescence in situ hybridization study. Hum Pathol 37:415-421, 2006.
65. Lusis E, Gutmann DH: Meningioma: an update. Curr Opin Neurol 17:687-692, 2004.
66. Maillo A, Orfao A, Sayagues JM, Diaz P, Gómez-Moreta JA, Caballero M, et al: New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology. J Clin Oncol 21:3285-3295, 2003.
67. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al: Meningioma. Crit Rev Oncol Hematol 67:153-171, 2008.
68. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, et al: Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med 16:771-774, 2005.
69. Mathiesen T, Kihlström L, Karlsson B, Lindquist C: Potential complications following radiotherapy for meningiomas. Surg Neurol 60:193-200, 2003.
70. Mawrin C, Perry A: Pathological classification and molecular genetics of meningiomas. J Neurooncol 99:379-391, 2010.
71. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al: Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074-4082, 2005.
72. McClatchey AI, Giovannini M: Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev 19:2265-2277, 2005.
73. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al: Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 12:1121-1133, 1998.
74. Mendiola M, Bello MJ, Alonso J, Leone PE, Vaquero J, Sarasa JL, et al: Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32. Mol Carcinog 24: 300-304, 1999.
75. Menon AG, Rutter JL, von Sattel JP, Synder H, Murdoch C, Blumenfeld A, et al: Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene 14:611-616, 1997.
76. Mérel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, et al: Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13:211-216, 1995.
77. Mihaila D, Gutiérrez JA, Rosenblum ML, Newsham IF, Bögler O, Rempel SA: Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers. Clin Cancer Res 9:4435-4442, 2003.
78. Mihaila D, Jankowski M, Gutiérrez JA, Rosenblum ML, Newsham IF, Bögler O, et al: Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival. Clin Cancer Res 9:4443-4451, 2003.
79. Modha A, Gutin PH: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538-550, 2005.
80. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980, 2001.
81. Nathoo N, Barnett GH, Golubic M: The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 57: 6-13, 2004.
82. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al: Phase II trials of erlotinib or geftinib in patients with recurrent meningioma. J Neurooncol 96:211-217, 2010.
83. Nozaki M, Tada M, Kashiwazaki H, Hamou MF, Diserens AC, Shinohe Y, et al: p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol 11:296-305, 2001.
84. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachami-mov AO, Ramesh V, et al: Inactivation patterns of NF2 and DAL-1/41B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135-139, 2005.
85. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Geh-ring M, et al: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8: 74-80, 1993.
86. Ozaki S, Nishizaki T, Ito H, Sasaki K: Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neurooncol 41:167-174, 1999.
87. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, et al: Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183:2283-2291, 1996.
88. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW: A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12:183-190, 2002.
89. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, et al: Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872-879, 2000.
90. Perry A, Gutmann DH, Reifenberger G: Molecular pathogenesis of meningiomas. J Neurooncol 70:183-202, 2004.
91. Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, et al: Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 24:3-8, 1998.
92. Pfster C, Ritz R, Pfrommer H, Bornemann A, Tatagiba MS, Roser F: Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas? Neurosurg Focus 23(4):E8, 2007.
93. Ragel BT, Jensen RL: Aberrant signaling pathways in meningiomas. J Neurooncol 99:315-324, 2010.
94. Ragel BT, Jensen RL: Molecular genetics of meningiomas. Neurosurg Focus 19(5):E9, 2005.
95. Ragel BT, Jensen RL, Couldwell WT: Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygen-ase-2 inhibitors. Neurosurg Focus 23(4): E7, 2007.
96. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT: Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109:588-597, 2007.
97. Riemenschneider MJ, Perry A, Reifenberger G: Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045-1054, 2006.
98. Rohringer M, Sutherland GR, Louw DF, Sima AA: Incidence and clinicopathological features of meningioma. J Neurosurg 71:665-672, 1989.
99. Ruiz i Altaba A, Mas C, Stecca B: The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol 17:438-447, 2007.
100. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ: Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allyl-amino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 9:3749-3755, 2003.
101. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, et al: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189-1193, 1995.
102. Sanson M, Cornu P: Biology of meningiomas. Acta Neurochir (Wien) 142:493-505, 2000.
103. Schmitz U, Mueller W, Weber M, Sévenet N, Delattre O, von Deimling A: INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 84:199-201, 2001.
104. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, et al: Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat Genet 18:354-359, 1998.
105. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 9:726-735, 1995.
106. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, et al: The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 1:63-72, 2001.
107. Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, et al: Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509, 1997.
108. Simon M, Park TW, Leuenroth S, Hans VH, Löning T, Schramm J: Telomerase activity and expression of the telom-erase catalytic subunit, hTERT, in meningioma progression. J Neurosurg 92:832-840, 2000.
109. Simon M, von Deimling A, Larson JJ, Wellenreuther R, Kaskel P, Waha A, et al: Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of 110. meningioma progression. Cancer Res 55:4696-4701, 1995.
110. Skiriute D, Tamasauskas S, Asmoniene V, Saferis V, Skauminas K, Deltuva V, et al: Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. J Neurooncol 102:89-94, 2011.
111. Sulman EP, White PS, Brodeur GM: Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene 23:1014-1020, 2004.
112. Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ, et al: Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 49:1029-1038, 2001.
113. Talora C, Sgroi DC, Crum CP, Dotto GP: Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 16:2252-2263, 2002.
114. Torp SH, Helseth E, Dalen A, Unsgaard G: Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue. APMIS 100:797-802, 1992.
115. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800, 1993.
116. Tse JY, Ng HK, Lau KM, Lo KW, Poon WS, Huang DP: Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Hum Pathol 28:779-785, 1997.
117. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S: ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126:391-401, 1994.
118. Varjosalo M, Taipale J: Hedgehog: functions and mechanisms. Genes Dev 22:2454-2472, 2008.
119. Verhagen A, Go KG, Visser GM, Blankenstein MA, Vaalburg W: The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: its relevance to expression of progesterone receptors in meningiomas. Br J Neurosurg 9:47-50, 1995.
120. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fass-bender F, Nagel J, et al: Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544-558, 2000.
121. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, et al: Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 64:223-228, 1995.
122. Wang Y, McMahon AP, Allen BL: Shifting paradigms in Hedgehog signaling. Curr Opin Cell Biol 19:159-165, 2007.
123. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, et al: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94:14719-14724, 1997.
124. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD: Medical therapies for meningiomas. J Neurooncol 99:365-378, 2010.
125. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, et al: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-oncol 11:853-860, 2009.
126. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al: The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25:2384-2394, 2005.
127. Xu HM, Gutmann DH: Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res 51: 403-415, 1998.
128. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K: Recurrence of meningiomas. Cancer 89:1102-1110, 2000.
129. Yang SY, Xu GM: Expression of PDGF and its receptor as well as their relationship to proliferating activity and apopto-sis of meningiomas in human meningiomas. J Clin Neurosci 8 (Suppl 1):49-53, 2001.
130. Yu T, Robb VA, Singh V, Gutmann DH, Newsham IF: The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J 365:783-789, 2002.
131. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S: Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 92:6414-6418, 1995.
132. Zang KD: Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 93:207-220, 2001.
133. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, et al: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8:13-23, 2005.
134. Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y, et al: Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 70:2350-2358, 2010.